MEDP Stock — Medpace Holdings, Inc.

Medpace Holdings, Inc. (MEDP)

Updated October 16, 2026.

MEDP is a Stock. Total return is 2125.5% over the past 10.2 years, 1814.7 points ahead of SPY at 310.8%.

Medpace Holdings is a clinical research services company that provides drug and medical device development services to the pharmaceutical, biotechnology, and medical device industries across North America, Europe, Asia, and other regions. The company offers services spanning the full clinical development lifecycle, including trial design, regulatory affairs, clinical monitoring, data management, and post-marketing support, along with specialized services such as bio-analytical laboratory testing and imaging services. The company does not currently have a regular distribution schedule. Medpace appeals to equity investors seeking exposure to the healthcare services and clinical research outsourcing sector.

MEDP performance versus SPY

Price and return data through 2026-10-16.

Total return is 2125.5% over the past 10.2 years, 1814.7 points ahead of SPY at 310.8%. Over the past year its total return — price change plus distributions reinvested — is 18.7%. Its deepest 1-year drawdown was 36.6%.

MEDP key facts

Asset type

Stock

Asset class

Equity

Inception date

08/11/2016

Distribution frequency

None

Last close

$618.47 (as of 2026-10-16)

Market cap

$17,262,521,268

Average volume

297570.0

Beta

1.181

Payout ratio

0.0%

P/E ratio

36.32

Forward P/E

31.9489

EPS

$17.03

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MEDP risks and drawbacks

The deepest 1-year drawdown on record here is 36.6%.

Who may consider MEDP — and who may not

It is a weaker fit for investors who need monthly cash flow (MEDP does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MEDP

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions